| Pegasys (pegylated interferon α -2a) / Roche |
NCT02736721: Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) |
|
|
| Completed | 3 | 41 | Europe | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Myelogenous Leukemia, Chronic | 11/10 | 11/10 | | |
2004-001622-24: Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic myeloid leukaemia |
|
|
| Ongoing | 3 | 50 | Europe | Glivec, Pegasys, Glivec (400mg), Glivec (800mg), Pegasys, Glivec (400mg), Glivec (800mg), Pegasys | Newcastle Hospital Trust | Chronic Myeloid Leukaemia (Chronic Phase) | | | | |
| Unknown status | 3 | 200 | Europe | Nilotinib (Tasigna ®), capsules of 150 mg, Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®) | Hospices Civils de Lyon, Novartis | Chronic Myeloid Leukemia | 01/18 | 08/19 | | |
| Unknown status | 3 | 118 | RoW | Peginterferon-α-2a, Pegasys® | Ministry of Health, Malaysia | Leukemia, Chronic Myeloid | 10/18 | 10/21 | | |
NCT02829775 / 2004-002093-30: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies |
|
|
| Completed | 2/3 | 9 | Canada, Europe, RoW | Pegylated Interferon Alfa-2a, Pegasys, Recombinant Interferon Alfa 2a, Roferon-A | Hoffmann-La Roche | Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma | 01/08 | 01/08 | | |
